gastric
No description yet: the sentence for this tag has not been written. 10 records carry it: 10 people.
10 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Florian Lordick Director, University Cancer Center Leipzig; Professor of Oncology, University of Leipzig · Leipzig University Hospital / University Cancer Center Leipzig (UCCL) German GI oncologist who leads ESMO's gastric cancer guidelines and pivotal perioperative trials. | Gastric & gastro-oesophageal junction cancer, Oesophageal cancer | none | guidelines, esmo | ||
Hansjochen Wilke Medical oncologist, Kliniken Essen-Mitte · Kliniken Essen-Mitte German oncologist who led RAINBOW, the trial that made ramucirumab plus paclitaxel a standard second-line treatment for advanced stomach cancer. | PD-L1-high gastric cancer, Gastric & gastro-oesophageal junction cancer | none | trialist | ||
Hitoshi Katai Gastric surgeon, National Cancer Center Hospital, Tokyo · National Cancer Center Hospital Japanese surgeon who led JCOG0912, the trial that confirmed laparoscopic gastrectomy is not inferior to open surgery for early stomach cancer. | Early gastric cancer, Gastric & gastro-oesophageal junction cancer | none | surgery, trialist | ||
Hyung-Ho Kim Gastric surgeon, Seoul National University Bundang Hospital · Seoul National University Bundang Hospital Korean surgeon who led KLASS-01, the trial that showed keyhole gastrectomy is as safe and effective as open surgery for early stomach cancer. | Early gastric cancer, Gastric & gastro-oesophageal junction cancer | none | surgery, trialist | ||
Jaffer A. Ajani Professor of Gastrointestinal Medical Oncology, MD Anderson Cancer Center · MD Anderson Cancer Center Gastro-oesophageal oncologist who co-led CheckMate 649, the trial that added nivolumab to first-line gastric cancer chemotherapy. | Gastric & gastro-oesophageal junction cancer, Oesophageal cancer | none | esophageal, immunotherapy | ||
Manish A. Shah Gastrointestinal medical oncologist, Weill Cornell Medicine · Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine New York oncologist who was lead author of GLOW, one of the two trials that established zolbetuximab, the first drug aimed at claudin 18.2, for stomach cancer. | Claudin 18.2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer | none | trialist | ||
Mitsuru Sasako Professor Emeritus, Hyogo College of Medicine; former Chief of Gastric Surgery, National Cancer Center Hospital Tokyo Japanese surgeon whose JCOG trials defined D2 gastrectomy and adjuvant S-1 as standards for gastric cancer. | Gastric & gastro-oesophageal junction cancer | none | surgery, japan | ||
Peter Thuss-Patience Medical oncologist, Charité Universitätsmedizin Berlin · Charité Universitätsmedizin Berlin Berlin oncologist who led GATSBY, the trial showing that the antibody-drug conjugate T-DM1 did not beat taxane chemotherapy in previously treated HER2-positive stomach cancer. | HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer | none | trialist | ||
Salah-Eddin Al-Batran Medical oncologist and trial lead, Krankenhaus Nordwest and Institute of Clinical Cancer Research, Frankfurt · Krankenhaus Nordwest / Institute of Clinical Cancer Research (IKF) German oncologist who led FLOT4, the trial that made the FLOT chemotherapy regimen the standard before and after surgery for stomach and oesophago-gastric junction cancer. | Oesophageal and junctional adenocarcinoma, HER2-positive gastric cancer, Oesophageal cancer | none | oesophageal, trialist | ||
Zev A. Wainberg Professor of Medicine and Co-Director, GI Oncology Program, UCLA Jonsson Comprehensive Cancer Center · UCLA Jonsson Comprehensive Cancer Center Led NAPOLI 3, the trial that made NALIRIFOX a first-line option for metastatic pancreatic cancer. | Pancreatic ductal adenocarcinoma, Gastric & gastro-oesophageal junction cancer | none | pancreatic, trialist |